利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

34 条记录 (耗时 0.016 秒)

    ARZNEIMITTEL ZUR BEHANDLUNG VON VIRALEN HAUT- UND TUMORERKRANKUNGEN
    25.
    发明公开
    ARZNEIMITTEL ZUR BEHANDLUNG VON VIRALEN HAUT- UND TUMORERKRANKUNGEN 有权

    公开(公告)号：EP1448186A1

    公开(公告)日：2004-08-25

    申请号：EP02803380.1

    申请日：2002-11-18

    申请人： MediGene Aktiengesellschaft

    发明人： CHANG, Yunik ,  LATHROP, Robert ,  BÖHM, Erwin ,  GANDER-MEISTERERNST, Irene ,  GREGER, Regina ,  HOLLDACK, Johanna ,  MOEBIUS, Ulrich

    IPC分类号： A61K31/23 ,  A61K31/25 ,  A61K31/353 ,  A61P17/00 ,  A61P31/20 ,  A61P31/22

    CPC分类号： A61K9/0014 ,  A61K31/23 ,  A61K31/353 ,  A61K47/06 ,  A61K47/10 ,  A61K47/14 ,  Y10S514/934 ,  Y10S514/947 ,  Y10S514/967 ,  Y10S514/969 ,  A61K2300/00

    摘要： The invention relates to a medicament containing a compound of general formula (I), where R1 = independently, a straight or branched, saturated, singly- or multiply-unsaturated, optionally substituted C11-C21 alkyl, alkylene or alkinyl group, preferably a C11-C15 alkyl, alkylene or alkinyl group, particularly a C11-C13 alkyl, alkylene or alkinyl group, most preferably a C13 alkyl group, R2 = independently, a straight or branched C1-C8 alkyl, alkylene or alkinyl group, preferably a C1-C6 alkyl, alkylene or alkinyl group, in particular a C2-C4 alkyl, alkylene or alkinyl group, most preferably a C3 alkyl group, a -[CH2-(CH2)m-O]nH group with n = 1 to 10, preferably n = 1 to 5, m = 1 to 5, preferably m = 1 to 3, a -CH2-[CH-(OH)]p [CH2-(R3)]- group, where R3 = independently H or OH, p = 1 to 7, preferably p = 1 to 4, a pentose group or a hexose group, as therapeutically active agent, alone or in combination with one or several further pharmaceutical agents as a combination preparation for the treatment of viral skin diseases and/or tumour diseases, in particular caused by human papilloma virus (HPV) and/or herpes viruses and a topically acting medicament formulation and the use thereof.

    摘要翻译： 新药含有高级链烷酸，链烯酸或炔炔酸酯（I）作为活性剂。 新药包含式R 1 COOR 2（I）的酯作为活性剂。 R 1选自11-15C（优选11-13C）烷基，烯基或炔基（包括多不饱和基团）; R 21-8C（优选2-4C）烷基，烯基或炔基， - （CH 2（CH 2）mO）nH - （CH 2（CH（OH））p-CH 2 3或戊糖或己糖残基; R 3 H或OH; n：1-10（优选1-5）; m：1-5（优选1-3）;和p：1-7（优选1-4）活性：病毒剂;皮肤病学;细胞抑制剂; 抗艾滋病毒在生殖器疣患者的试验中，施用包含35重量％肉豆蔻酸异丙酯（Ia），25重量％白蜡，34.023重量％白凡士林，5重量％丙二醇单硬脂酸酯，0.5重量％ 重量％油醇，0.022重量％红氧化铁，0.055重量％黄氧化铁和0.400重量％二氧化钛，每天3次，持续12周（或直至固化完成）在42.1％的男性患者中完全治愈 女性患者33.3％，男性患者63.2％，女性患者52.4％，部分（至少75％）治愈。

    TESTSYSTEM ZUM IN VITRO NACHWEIS EINER ANTIGEN-SPEZIFISCHEN IMMUNANTWORT
    30.
    发明公开
    TESTSYSTEM ZUM IN VITRO NACHWEIS EINER ANTIGEN-SPEZIFISCHEN IMMUNANTWORT 审中-公开
    测试系统在体外抗原检测特异性免疫反应

    公开(公告)号：EP1183533A1

    公开(公告)日：2002-03-06

    申请号：EP00936845.7

    申请日：2000-05-31

    申请人： MediGene Aktiengesellschaft

    发明人： JOCHMUS, Ingrid ,  NIELAND, John

    IPC分类号： G01N33/50

    CPC分类号： C12N5/0639 ,  C12N2501/23 ,  C12N2501/24

    摘要： The invention relates to a test system comprising at least one capsomer, at least one stable capsomer, at least one capsid, at least one VLP and/or at least one CVLP and at least one target cell presenting an antigen, especially a B cell, a macrophage, a predendritic cell, a dendritic cell, embryonal cell and/or fibroblast, which has been incubated with at least one capsomer, at least one stable capsomer, at least one capsid, at least one VLP and/or at least one CVLP, in order to detect an antigen-specific immune response in vitro, especially a cellular immune response from effector cells of the immune system, especially B cells, NK cells, preferably T cells, more preferably cytotoxic T cells or helper T cells. The invention also relates to the use thereof in diagnosis and therapy.